Concepts (172)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uterine Cervical Neoplasms | 13 | 2020 | 145 | 1.300 |
Why?
|
| Papillomavirus Infections | 11 | 2020 | 123 | 1.290 |
Why?
|
| Cell Biology | 3 | 2021 | 21 | 1.160 |
Why?
|
| Pathologists | 3 | 2021 | 11 | 0.940 |
Why?
|
| Vaginal Smears | 6 | 2010 | 52 | 0.870 |
Why?
|
| Cytodiagnosis | 6 | 2022 | 43 | 0.800 |
Why?
|
| Cytological Techniques | 4 | 2023 | 23 | 0.770 |
Why?
|
| Papillomaviridae | 7 | 2020 | 58 | 0.730 |
Why?
|
| Early Detection of Cancer | 5 | 2020 | 260 | 0.460 |
Why?
|
| Symbiosis | 2 | 2023 | 29 | 0.440 |
Why?
|
| Pathology, Clinical | 3 | 2010 | 21 | 0.370 |
Why?
|
| Hysterectomy | 2 | 2009 | 70 | 0.360 |
Why?
|
| Mass Screening | 7 | 2020 | 638 | 0.330 |
Why?
|
| Cystadenocarcinoma, Papillary | 1 | 2009 | 3 | 0.330 |
Why?
|
| Peritoneal Lavage | 1 | 2009 | 4 | 0.330 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2009 | 12 | 0.330 |
Why?
|
| Lymphoma | 1 | 2010 | 98 | 0.330 |
Why?
|
| Pleural Effusion | 1 | 2009 | 33 | 0.330 |
Why?
|
| Peritoneal Neoplasms | 1 | 2009 | 22 | 0.320 |
Why?
|
| Carbon | 1 | 2009 | 45 | 0.320 |
Why?
|
| HIV Seropositivity | 1 | 2009 | 82 | 0.320 |
Why?
|
| Ovarian Neoplasms | 1 | 2009 | 130 | 0.300 |
Why?
|
| Practice Guidelines as Topic | 5 | 2015 | 701 | 0.300 |
Why?
|
| Uterine Cervical Dysplasia | 2 | 2020 | 28 | 0.290 |
Why?
|
| Quality Assurance, Health Care | 1 | 2010 | 244 | 0.290 |
Why?
|
| Unnecessary Procedures | 1 | 2007 | 40 | 0.290 |
Why?
|
| Neuroectodermal Tumor, Melanotic | 1 | 2006 | 3 | 0.270 |
Why?
|
| Scrotum | 1 | 2006 | 4 | 0.270 |
Why?
|
| Genital Diseases, Male | 1 | 2006 | 9 | 0.270 |
Why?
|
| Epididymis | 1 | 2006 | 27 | 0.270 |
Why?
|
| Acantholysis | 1 | 2005 | 5 | 0.260 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2005 | 6 | 0.260 |
Why?
|
| Pemphigus | 1 | 2005 | 14 | 0.260 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2005 | 32 | 0.260 |
Why?
|
| Schools | 2 | 2023 | 156 | 0.260 |
Why?
|
| Cervix Uteri | 1 | 2005 | 57 | 0.250 |
Why?
|
| Humans | 37 | 2023 | 59068 | 0.250 |
Why?
|
| Aged, 80 and over | 9 | 2015 | 5060 | 0.240 |
Why?
|
| DNA Probes, HPV | 2 | 2014 | 3 | 0.230 |
Why?
|
| Adult | 17 | 2020 | 15677 | 0.230 |
Why?
|
| Middle Aged | 16 | 2020 | 16194 | 0.230 |
Why?
|
| Breast Neoplasms | 4 | 2005 | 1119 | 0.230 |
Why?
|
| Female | 26 | 2020 | 30700 | 0.220 |
Why?
|
| Macrophages | 1 | 2009 | 1003 | 0.220 |
Why?
|
| DNA, Viral | 2 | 2014 | 228 | 0.210 |
Why?
|
| Curriculum | 2 | 2023 | 543 | 0.200 |
Why?
|
| Immunohistochemistry | 4 | 2010 | 846 | 0.200 |
Why?
|
| Papanicolaou Test | 4 | 2014 | 40 | 0.200 |
Why?
|
| Pathology | 1 | 2021 | 11 | 0.190 |
Why?
|
| Biopsy, Fine-Needle | 4 | 2010 | 63 | 0.190 |
Why?
|
| Certification | 1 | 2021 | 48 | 0.190 |
Why?
|
| Lung Neoplasms | 2 | 2022 | 546 | 0.170 |
Why?
|
| Medical Oncology | 1 | 2020 | 56 | 0.170 |
Why?
|
| Aged | 11 | 2020 | 13265 | 0.160 |
Why?
|
| Consensus | 1 | 2020 | 190 | 0.160 |
Why?
|
| Education, Medical, Graduate | 1 | 2021 | 300 | 0.160 |
Why?
|
| Workplace | 1 | 2020 | 180 | 0.160 |
Why?
|
| Precancerous Conditions | 2 | 2010 | 72 | 0.150 |
Why?
|
| Adolescent | 5 | 2014 | 5896 | 0.130 |
Why?
|
| Biopsy, Needle | 3 | 2014 | 126 | 0.130 |
Why?
|
| Granulomatosis with Polyangiitis | 1 | 1995 | 14 | 0.120 |
Why?
|
| Papilloma | 2 | 2007 | 12 | 0.120 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2015 | 29 | 0.120 |
Why?
|
| Sensitivity and Specificity | 4 | 2014 | 1092 | 0.120 |
Why?
|
| False Negative Reactions | 2 | 2014 | 40 | 0.120 |
Why?
|
| Human Papillomavirus DNA Tests | 1 | 2014 | 1 | 0.120 |
Why?
|
| North America | 2 | 2023 | 109 | 0.110 |
Why?
|
| Reproducibility of Results | 5 | 2010 | 1540 | 0.110 |
Why?
|
| Young Adult | 5 | 2020 | 4301 | 0.110 |
Why?
|
| Staining and Labeling | 2 | 2011 | 123 | 0.100 |
Why?
|
| Retrospective Studies | 3 | 2010 | 5951 | 0.100 |
Why?
|
| Colposcopy | 3 | 2020 | 22 | 0.100 |
Why?
|
| False Positive Reactions | 2 | 2010 | 74 | 0.100 |
Why?
|
| Biomarkers, Tumor | 2 | 2007 | 453 | 0.100 |
Why?
|
| Azo Compounds | 1 | 2011 | 6 | 0.090 |
Why?
|
| Diagnosis, Differential | 3 | 2009 | 894 | 0.090 |
Why?
|
| Ultrasonography | 4 | 2007 | 449 | 0.090 |
Why?
|
| Pathology, Surgical | 1 | 2011 | 12 | 0.090 |
Why?
|
| Biopsy | 2 | 2021 | 373 | 0.090 |
Why?
|
| Laboratories | 1 | 2010 | 27 | 0.090 |
Why?
|
| Crack Cocaine | 1 | 2009 | 7 | 0.080 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2009 | 19 | 0.080 |
Why?
|
| Omentum | 1 | 2009 | 12 | 0.080 |
Why?
|
| Uterine Cervical Diseases | 1 | 2009 | 4 | 0.080 |
Why?
|
| Male | 7 | 2015 | 27390 | 0.080 |
Why?
|
| Cocaine-Related Disorders | 1 | 2009 | 75 | 0.080 |
Why?
|
| Calcinosis | 1 | 2009 | 78 | 0.080 |
Why?
|
| Health Occupations | 1 | 2008 | 10 | 0.080 |
Why?
|
| Diagnostic Errors | 1 | 2009 | 98 | 0.070 |
Why?
|
| Glypicans | 1 | 2007 | 6 | 0.070 |
Why?
|
| Flow Cytometry | 1 | 2010 | 667 | 0.070 |
Why?
|
| Antigens, CD | 1 | 2009 | 341 | 0.070 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2009 | 168 | 0.070 |
Why?
|
| Image Enhancement | 1 | 2009 | 190 | 0.070 |
Why?
|
| Thyroid Nodule | 1 | 2007 | 13 | 0.070 |
Why?
|
| Aspergillosis, Allergic Bronchopulmonary | 1 | 2006 | 9 | 0.070 |
Why?
|
| Calcium Oxalate | 1 | 2006 | 11 | 0.070 |
Why?
|
| Aspergillus | 1 | 2006 | 10 | 0.070 |
Why?
|
| Salivary Glands | 1 | 2006 | 46 | 0.070 |
Why?
|
| Thyroid Gland | 1 | 2007 | 78 | 0.070 |
Why?
|
| Health Services Needs and Demand | 1 | 2008 | 213 | 0.070 |
Why?
|
| Hematoxylin | 2 | 2022 | 11 | 0.070 |
Why?
|
| Eosine Yellowish-(YS) | 2 | 2022 | 12 | 0.070 |
Why?
|
| Lung | 2 | 2011 | 821 | 0.070 |
Why?
|
| Trichomonas vaginalis | 1 | 2005 | 8 | 0.060 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2007 | 166 | 0.060 |
Why?
|
| Cholesterol | 1 | 2007 | 256 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2005 | 52 | 0.060 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2005 | 44 | 0.060 |
Why?
|
| Cell Nucleus | 1 | 2009 | 602 | 0.060 |
Why?
|
| Infant | 2 | 2007 | 1518 | 0.060 |
Why?
|
| Liver Neoplasms | 1 | 2007 | 275 | 0.060 |
Why?
|
| Child, Preschool | 1 | 2010 | 1823 | 0.060 |
Why?
|
| Pleural Effusion, Malignant | 1 | 2003 | 6 | 0.060 |
Why?
|
| Vimentin | 1 | 2003 | 18 | 0.060 |
Why?
|
| Leukocyte Common Antigens | 1 | 2003 | 54 | 0.060 |
Why?
|
| Carcinoma, Small Cell | 1 | 2003 | 19 | 0.060 |
Why?
|
| Child | 2 | 2011 | 4259 | 0.060 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2004 | 54 | 0.060 |
Why?
|
| Intraoperative Period | 1 | 2003 | 34 | 0.050 |
Why?
|
| Educational Status | 1 | 2023 | 270 | 0.050 |
Why?
|
| Endosonography | 1 | 2022 | 33 | 0.050 |
Why?
|
| Accreditation | 1 | 2021 | 69 | 0.050 |
Why?
|
| Specialization | 1 | 2021 | 73 | 0.050 |
Why?
|
| Laboratories, Hospital | 1 | 2020 | 9 | 0.040 |
Why?
|
| Breast | 1 | 2002 | 172 | 0.040 |
Why?
|
| United States | 3 | 2021 | 7460 | 0.040 |
Why?
|
| Risk | 1 | 2020 | 370 | 0.040 |
Why?
|
| Genotype | 1 | 2020 | 642 | 0.040 |
Why?
|
| Observer Variation | 2 | 2011 | 201 | 0.040 |
Why?
|
| Crystallization | 2 | 2007 | 97 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2021 | 669 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 2 | 2007 | 104 | 0.030 |
Why?
|
| Gingival Diseases | 1 | 1995 | 1 | 0.030 |
Why?
|
| Human papillomavirus 18 | 1 | 2015 | 4 | 0.030 |
Why?
|
| Orbital Diseases | 1 | 1995 | 9 | 0.030 |
Why?
|
| Mediastinal Diseases | 1 | 1995 | 13 | 0.030 |
Why?
|
| Retroperitoneal Space | 1 | 1995 | 20 | 0.030 |
Why?
|
| Human papillomavirus 16 | 1 | 2015 | 17 | 0.030 |
Why?
|
| Breast Diseases | 1 | 1995 | 39 | 0.030 |
Why?
|
| Algorithms | 1 | 2020 | 985 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2015 | 89 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2014 | 95 | 0.030 |
Why?
|
| Forecasting | 1 | 2014 | 218 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2014 | 186 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2015 | 3080 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2007 | 1022 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2014 | 295 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2014 | 435 | 0.020 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2011 | 13 | 0.020 |
Why?
|
| Respiratory Aspiration | 1 | 2011 | 6 | 0.020 |
Why?
|
| Incidence | 1 | 2014 | 1232 | 0.020 |
Why?
|
| Coloring Agents | 1 | 2011 | 54 | 0.020 |
Why?
|
| Macrophages, Alveolar | 1 | 2011 | 59 | 0.020 |
Why?
|
| Telepathology | 1 | 2009 | 6 | 0.020 |
Why?
|
| Photography | 1 | 2009 | 43 | 0.020 |
Why?
|
| Neutrophils | 1 | 2011 | 351 | 0.020 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 1 | 2007 | 4 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2014 | 1901 | 0.020 |
Why?
|
| Tissue Fixation | 1 | 2007 | 23 | 0.020 |
Why?
|
| Cysts | 1 | 2007 | 37 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2006 | 270 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2007 | 321 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2007 | 915 | 0.010 |
Why?
|
| Stereotaxic Techniques | 1 | 2004 | 28 | 0.010 |
Why?
|
| Antibodies | 1 | 2003 | 176 | 0.010 |
Why?
|
| Vacuum | 1 | 2002 | 9 | 0.010 |
Why?
|
| Dilatation, Pathologic | 1 | 2002 | 28 | 0.010 |
Why?
|
| Equipment Design | 1 | 2003 | 313 | 0.010 |
Why?
|
| Mammography | 1 | 2004 | 271 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2003 | 413 | 0.010 |
Why?
|
| Animals | 1 | 2005 | 19552 | 0.000 |
Why?
|